Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-B4GALNT1, 14.18 mAb Vector   (CAT#: GTVCR-WQ48MR)

This product GTVCR-WQ48MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting B4GALNT1. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Chimeric
RefSeq NM_001276468.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-B4GALNT1, 14.18 mAb Vector (GTVCR-WQ48MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2222MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, PF-06252616 Vector Vector PF-06252616
GTVCR-WQ740MR IVTScrip™ pT7-VEE-mRNA-Anti-B7, BMS-224818 Vector Vector BMS-224818
GTVCR-WQ479MR IVTScrip™ pT7-VEE-mRNA-Anti-NGF, AMG-403 Vector Vector AMG-403
GTVCR-WQ301MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL2RA, ADCT-301 Vector Vector ADCT-301
GTVCR-WQ975MR IVTScrip™ pT7-VEE-mRNA-Anti-CD40, CFZ-533 Vector Vector CFZ-533
GTVCR-WQ2486MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD33, SGN-CD33A Vector Vector SGN-CD33A
GTVCR-WQ749MR IVTScrip™ pSP6-VEE-mRNA-Anti-CTLA4, BMS-734016 Vector Vector BMS-734016
GTVCR-WQ1343MR IVTScrip™ pT7-VEE-mRNA-Anti-CD52, GZ-402668 Vector Vector GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW